# Early nail involvement in mycosis fungoides with rapid systemic progression: rethinking the role of Ki-67: a case report

**Authors:** Shafagh Ali Asgarzadeh, Amir Arshia Beheshti

PMC · DOI: 10.1186/s13256-025-05582-8 · Journal of Medical Case Reports · 2025-10-31

## TL;DR

A patient with mycosis fungoides showed early nail changes and rapid disease progression despite low Ki-67 levels, highlighting the need for better prognostic tools.

## Contribution

Highlights early nail involvement and limited utility of Ki-67 in predicting aggressive mycosis fungoides.

## Key findings

- Early nail changes may indicate atypical progression in mycosis fungoides.
- Low Ki-67 index did not prevent rapid systemic disease progression.
- Comprehensive models with molecular biomarkers may improve prognosis.

## Abstract

Mycosis fungoides, the most common cutaneous T-cell lymphoma, typically exhibits a gradual progression. However, aggressive forms with extracutaneous involvement and low proliferative indices may present diagnostic and prognostic challenges. Nail involvement appears to be infrequent and poorly understood, and is often considered a late-stage manifestation. The Ki-67 index, although frequently utilized as an indicator of tumor aggressiveness, may have limitations in specific mycosis fungoides subtypes that appear to be influenced by distinct molecular or immunological pathways.

We present a 62-year-old Iranian woman with early stage mycosis fungoides, exhibiting erythematous abdominal plaques, pruritus, and early onset onychodystrophy. Within 4 months, the lesions rapidly progressed to painful plaques affecting the face and intertriginous areas. The initial biopsy revealed features consistent with plaque-stage mycosis fungoides, characterized by CD4 predominance, CD7 deficiency, and a low Ki-67 index (< 5%). Despite low proliferation indices, the disease progressed rapidly. Imaging revealed bilateral lymphadenopathy, and a subsequent biopsy confirmed ongoing disease, with limited CD8 expression, absent B-cell markers, and Ki-67 levels of 1–3%. The treatment regimen comprised methotrexate, interferon-alpha, and psoralen and ultraviolet A therapy. Partial cutaneous response was achieved; however, systemic progression occurred. Laboratory results revealed leukocytosis, elevated lactate dehydrogenase levels, and hepatic impairment. Bone marrow biopsies suggested early dissemination. Peripheral blood flow cytometry and nail biopsy were not conducted. The patient ultimately developed multiorgan failure and was transitioned to palliative care.

This case suggests the potential for aggressive mycosis fungoides behavior despite indolent histopathological characteristics. Initial nail involvement might serve as a clinical marker of atypical progression. The limitations of Ki-67 alone suggest the need for comprehensive prognostic models that incorporate molecular biomarkers, such as thymocyte selection-associated high mobility group box, CD30, and T-cell receptor clonality.

## Linked entities

- **Proteins:** Mki67 (antigen identified by monoclonal antibody Ki 67), CD4 (CD4 molecule), CD7 (CD7 molecule), CD8A (CD8 subunit alpha)
- **Chemicals:** methotrexate (PubChem CID 4112), psoralen (PubChem CID 6199)
- **Diseases:** mycosis fungoides (MONDO:0009691), cutaneous T-cell lymphoma (MONDO:0000607), multiorgan failure (MONDO:0043726)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TNFRSF8 (TNF receptor superfamily member 8) [NCBI Gene 943] {aka CD30, D1S166E, Ki-1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** multiorgan failure (MESH:D051437), tumor (MESH:D009369), Mycosis fungoides (MESH:D009182), lymphadenopathy (MESH:D008206), CD7 deficiency (MESH:D007153), pruritus (MESH:D011537), cutaneous T-cell lymphoma (MESH:D016410), onychodystrophy (OMIM:614149), hepatic impairment (MESH:D008107), leukocytosis (MESH:D007964), erythematous abdominal plaques (MESH:D000007)
- **Chemicals:** methotrexate (MESH:D008727), psoralen (MESH:D005363), ultraviolet A (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12577402/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12577402/full.md

---
Source: https://tomesphere.com/paper/PMC12577402